Margalit R
Department of Biochemistry, Tel Aviv University, Israel.
Crit Rev Ther Drug Carrier Syst. 1995;12(2-3):233-61. doi: 10.1615/critrevtherdrugcarriersyst.v12.i2-3.30.
Liposome-mediated drug targeting is reviewed in four major categories of topical and regional therapies: wounds and burns, ocular, intraperitoneal, and pulmonary. A survey of the data in the field is preceded by definitions of carrier-mediated drug targeting, in particular for topical and regional treatments. The ability of liposomes to meet essential requirements for task performance and liposome surface-modification as the major approach to endow liposomes with targeting abilities are reviewed. Analysis of current findings in the field shows that (1) most studies explored regular liposomes that were unable to meet the essential requirements for targeting and (2) in vivo drug targeting in topical and regional therapies has been achieved rarely and seldom attempted, yet there are encouraging indications from a few studies that using surface-modified liposomes such targeting is feasible. Both established and novel liposomal systems attest to this feasibility and point out future directions. The former can be found by revisiting immunoliposomes that were initially designed for systemic administration but might well fit topical and regional cases. The latter is exemplified by bioadhesive liposomes, designed specifically for topical/regional therapies. It is concluded that careful implementation of such approaches could be successful for the achievement of liposome-mediated drug targeting in topical and regional therapies.
伤口与烧伤、眼部、腹腔内和肺部。在对该领域的数据进行调查之前，先对载体介导的药物靶向作用进行了定义，特别是针对局部和区域治疗的定义。综述了脂质体满足任务执行基本要求的能力以及作为赋予脂质体靶向能力的主要方法的脂质体表面修饰。对该领域当前研究结果的分析表明：（1）大多数研究探索的常规脂质体无法满足靶向的基本要求；（2）局部和区域治疗中的体内药物靶向作用很少实现且很少有人尝试，然而一些研究有令人鼓舞的迹象表明，使用表面修饰的脂质体这种靶向作用是可行的。既定的和新型的脂质体系统都证明了这种可行性，并指出了未来的方向。前者可以通过回顾最初为全身给药设计但很可能适用于局部和区域情况的免疫脂质体找到。后者以专门为局部/区域治疗设计的生物黏附脂质体为例。得出的结论是，谨慎实施这些方法可能会成功实现脂质体介导的局部和区域治疗中的药物靶向作用。
